These results align with the findings of Xiaoyan Sheng et al., who showed that targeting the liver X receptor to suppress SREBP-1c transcriptional activity and its downstream lipogenic enzymes, as well as participating in immune regulation associated with hepatic steatosis, could significantly improve NAFLD (Sheng et al. 2011). Here, SREBF1 is linked to Hepatic steatosis.